PTC
IMRX icon

Private Trust Company’s Immuneering IMRX Stock Holding History

Private Trust Company’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25K Buy
+250
New +$1.26K ﹤0.01% 2570

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Private Trust Company's IMRX Position: Q2 2026 in Review

Private Trust Company opened a new position in Immuneering (IMRX) in Q2 2026: 250 shares worth $1.25K. The stake represents ﹤0.01% of the portfolio and ranks #2570 among its holdings.

112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Private Trust Company held 250 shares of Immuneering worth $1.25K as of Q2 2026.
  • Immuneering was a new Private Trust Company position in Q2 2026.
  • Immuneering made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #2570 holding.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.